000893314 001__ 893314
000893314 005__ 20230111074310.0
000893314 0247_ $$2doi$$a10.1038/s41398-020-01085-w
000893314 0247_ $$2Handle$$a2128/28000
000893314 0247_ $$2pmid$$a33235193
000893314 0247_ $$2WOS$$aWOS:000596251600001
000893314 037__ $$aFZJ-2021-02688
000893314 082__ $$a610
000893314 1001_ $$0P:(DE-HGF)0$$aHohoff, Christa$$b0$$eCorresponding author
000893314 245__ $$aADORA2A variation and adenosine A1 receptor availability in the human brain with a focus on anxiety-related brain regions: modulation by ADORA1 variation
000893314 260__ $$aLondon$$bNature Publishing Group$$c2020
000893314 3367_ $$2DRIVER$$aarticle
000893314 3367_ $$2DataCite$$aOutput Types/Journal article
000893314 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625214232_4883
000893314 3367_ $$2BibTeX$$aARTICLE
000893314 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893314 3367_ $$00$$2EndNote$$aJournal Article
000893314 520__ $$aAdenosine, its interacting A1 and A2A receptors, and particularly the variant rs5751876 in the A2A gene ADORA2A have been shown to modulate anxiety, arousal, and sleep. In a pilot positron emission tomography (PET) study in healthy male subjects, we suggested an effect of rs5751876 on in vivo brain A1 receptor (A1AR) availability. As female sex and adenosinergic/dopaminergic interaction partners might have an impact on this rs5751876 effect on A1AR availability, we aimed to (1) further investigate the pilot male-based findings in an independent, newly recruited cohort including women and (2) analyze potential modulation of this rs5751876 effect by additional adenosinergic/dopaminergic gene variation. Healthy volunteers (32/11 males/females) underwent phenotypic characterization including self-reported sleep and A1AR-specific quantitative PET. Rs5751876 and 31 gene variants of adenosine A1,A2A,A2B, and A3 receptors, adenosine deaminase, and dopamine D2 receptor were genotyped. Multivariate analysis revealed an rs5751876 effect on A1AR availability (P=0.047), post hoc confirmed in 30 of 31 brain regions (false discovery rate (FDR) corrected P values<0.05), but statistically stronger in anxiety-related regions (e.g., amygdala, hippocampus). Additional effects of ADORA1 rs1874142 were identified; under its influence rs5751876 and rs5751876 × sleep had strengthened effects on A1AR availability (Pboth <0.02; post hoc FDR-corrected Ps<0.05 for 29/30 regions, respectively). Our results support the relationship between rs5751876 and A1AR availability. Additional impact of rs1874142, together with rs5751876 and sleep, might be involved in regulating arousal and thus the development of mental disorders like anxiety disorders. The interplay of further detected suggestive ADORA2A × DRD2 interaction, however, necessitates larger future samples more comparable to magnetic resonance imaging (MRI)-based samples.
000893314 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000893314 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893314 7001_ $$0P:(DE-Juel1)131691$$aKroll, Tina$$b1
000893314 7001_ $$0P:(DE-HGF)0$$aZhao, Baoyuan$$b2
000893314 7001_ $$00000-0003-0565-0988$$aKerkenberg, Nicole$$b3
000893314 7001_ $$00000-0002-7202-5982$$aLang, Ilona$$b4
000893314 7001_ $$0P:(DE-HGF)0$$aSchwarte, Kathrin$$b5
000893314 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, David$$b6
000893314 7001_ $$00000-0003-0336-6705$$aElmenhorst, Eva-Maria$$b7
000893314 7001_ $$0P:(DE-HGF)0$$aAeschbach, Daniel$$b8
000893314 7001_ $$00000-0002-4166-2970$$aZhang, Weiqi$$b9
000893314 7001_ $$00000-0001-6548-426X$$aBaune, Bernhard T.$$b10
000893314 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b11
000893314 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b12
000893314 7001_ $$00000-0003-1008-4650$$aDeckert, Jürgen$$b13
000893314 773__ $$0PERI:(DE-600)2609311-X$$a10.1038/s41398-020-01085-w$$gVol. 10, no. 1, p. 406$$n1$$p406$$tTranslational Psychiatry$$v10$$x2158-3188$$y2020
000893314 8564_ $$uhttps://juser.fz-juelich.de/record/893314/files/s41398-020-01085-w.pdf$$yOpenAccess
000893314 909CO $$ooai:juser.fz-juelich.de:893314$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893314 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich$$b1$$kFZJ
000893314 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich$$b6$$kFZJ
000893314 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b11$$kFZJ
000893314 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b12$$kFZJ
000893314 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000893314 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000893314 9141_ $$y2021
000893314 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000893314 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000893314 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL PSYCHIAT : 2019$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893314 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bTRANSL PSYCHIAT : 2019$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-29
000893314 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000893314 920__ $$lyes
000893314 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000893314 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000893314 980__ $$ajournal
000893314 980__ $$aVDB
000893314 980__ $$aUNRESTRICTED
000893314 980__ $$aI:(DE-Juel1)INM-5-20090406
000893314 980__ $$aI:(DE-Juel1)INM-2-20090406
000893314 9801_ $$aFullTexts